gamma-aminobutyric acid has been researched along with Panic Disorder in 42 studies
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.
Panic Disorder: A type of anxiety disorder characterized by unexpected panic attacks that last minutes or, rarely, hours. Panic attacks begin with intense apprehension, fear or terror and, often, a feeling of impending doom. Symptoms experienced during a panic attack include dyspnea or sensations of being smothered; dizziness, loss of balance or faintness; choking sensations; palpitations or accelerated heart rate; shakiness; sweating; nausea or other form of abdominal distress; depersonalization or derealization; paresthesias; hot flashes or chills; chest discomfort or pain; fear of dying and fear of not being in control of oneself or going crazy. Agoraphobia may also develop. Similar to other anxiety disorders, it may be inherited as an autosomal dominant trait.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A randomized, double-blind, placebo-controlled, parallel-group study was conducted to evaluate the efficacy and safety of gabapentin in relieving the symptoms of panic disorder." | 9.09 | Placebo-controlled study of gabapentin treatment of panic disorder. ( Chouinard, G; Crockatt, J; Dager, SR; Greiner, M; Lydiard, RB; Pande, AC; Pollack, MH; Shiovitz, T; Taylor, CB, 2000) |
| "Cerebrospinal fluid (CSF) gamma-aminobutyric acid (GABA) levels were measured in 11 patients with panic disorder (PD) prior to and following 7 months of treatment with alprazolam or imipramine and in six neurological control patients." | 9.08 | Cerebrospinal fluid gamma-aminobutyric acid in patients with panic disorder. ( Halonen, T; Jolkkonen, J; Lepola, U; Riekkinen, P; Rimón, R, 1995) |
| "Panic disorder (PD) is hypothesized to be associated with altered function of the major inhibitory neurotransmitter, gamma-aminobutyric acid (GABA)." | 7.75 | Prefrontal cortical gamma-aminobutyric Acid levels in panic disorder determined by proton magnetic resonance spectroscopy. ( Drevets, WC; Geraci, M; Hasler, G; Pine, D; Shen, J; van der Veen, JW, 2009) |
| "Low levels of gamma-aminobutyric acid (GABA) in plasma have been associated with the presence of mood disorders in patients with major depressive disorder." | 7.69 | Plasma levels of gamma-aminobutyric acid and panic disorder. ( Davis, LL; Germine, M; Goddard, AW; Kramer, GL; Narayan, M; Petty, F; Woods, SW, 1996) |
| "Sodium valproate (VA) and clonazepam (CLZ) were combined in the treatment of 4 patients with panic disorders (PD) who were resistant to several antipanic drug treatments." | 7.68 | Sodium valproate and clonazepam for treatment-resistant panic disorder. ( Fontaine, R; Ontiveros, A, 1992) |
| " A significant improvement was found in the symptomatology of these patients, but relapses occurred when CLZ dosage was reduced." | 5.28 | Sodium valproate and clonazepam for treatment-resistant panic disorder. ( Fontaine, R; Ontiveros, A, 1992) |
| " Here, we found that the translocator protein (18 kD) ligand XBD173 enhanced gamma-aminobutyric acid-mediated neurotransmission and counteracted induced panic attacks in rodents in the absence of sedation and tolerance development." | 5.14 | Translocator protein (18 kD) as target for anxiolytics without benzodiazepine-like side effects. ( Baghai, TC; Bertaina-Anglade, V; Chaperon, F; Eser, D; Floesser, A; Gentsch, C; Holsboer, F; Kalkman, HO; Kiese, B; Kucher, K; La Rochelle, CD; Landgraf, R; McAllister, KH; Nothdurfter, C; Rammes, G; Rupprecht, R; Schüle, C; Schumacher, M; Troxler, T; Tuerck, D; Uzunov, V, 2009) |
| "A randomized, double-blind, placebo-controlled, parallel-group study was conducted to evaluate the efficacy and safety of gabapentin in relieving the symptoms of panic disorder." | 5.09 | Placebo-controlled study of gabapentin treatment of panic disorder. ( Chouinard, G; Crockatt, J; Dager, SR; Greiner, M; Lydiard, RB; Pande, AC; Pollack, MH; Shiovitz, T; Taylor, CB, 2000) |
| "Six subjects with panic disorder underwent sodium lactate infusions in conjunction with magnetic resonance spectroscopic imaging (MRSI) at study entrance when actively symptomatic and after clinical improvement while under treatment with gabapentin." | 5.09 | Brain metabolic changes during lactate-induced panic: effects of gabapentin treatment. ( Dager, SR; Friedman, SD; Layton, ME, 2001) |
| "Cerebrospinal fluid (CSF) gamma-aminobutyric acid (GABA) levels were measured in 11 patients with panic disorder (PD) prior to and following 7 months of treatment with alprazolam or imipramine and in six neurological control patients." | 5.08 | Cerebrospinal fluid gamma-aminobutyric acid in patients with panic disorder. ( Halonen, T; Jolkkonen, J; Lepola, U; Riekkinen, P; Rimón, R, 1995) |
| "The acute effects of diazepam on plasma GABA were determined in 18 patients with panic disorder, 13 patients with generalized anxiety disorder and 20 healthy controls." | 5.07 | Effect of acute and chronic benzodiazepines on plasma GABA in anxious patients and controls. ( Cowley, DS; Greenblatt, DJ; Hommer, D; Kramer, GL; Petty, F; Roy-Byrne, PP, 1992) |
| ") sodium lactate (NaLac) infusions, in a manner similar to what occurs in patients with panic disorder." | 3.79 | Group II metabotropic glutamate receptor type 2 allosteric potentiators prevent sodium lactate-induced panic-like response in panic-vulnerable rats. ( Engleman, EA; Fitz, SD; Johnson, PL; Schkeryantz, JM; Shekhar, A; Svensson, KA, 2013) |
| " Adult male rats with chronic reduction of GABA levels (by inhibition of GABA synthesis with l-allyglycine, a glutamic acid decarboxylase inhibitor) in the dorsomedial/perifornical hypothalamus are highly anxious and exhibit physiological and behavioural responses to intravenous NaLac infusions similar to patients with panic disorder." | 3.77 | A selective, non-peptide CRF receptor 1 antagonist prevents sodium lactate-induced acute panic-like responses. ( Chaki, S; Fitz, SD; Johnson, PL; Nakazato, A; Schmidt, M; Shekhar, A; Steckler, T, 2011) |
| "Panic disorder (PD) is hypothesized to be associated with altered function of the major inhibitory neurotransmitter, gamma-aminobutyric acid (GABA)." | 3.75 | Prefrontal cortical gamma-aminobutyric Acid levels in panic disorder determined by proton magnetic resonance spectroscopy. ( Drevets, WC; Geraci, M; Hasler, G; Pine, D; Shen, J; van der Veen, JW, 2009) |
| "The purpose of this study was to investigate the brain gamma-aminobutyric acid (GABA) concentration and its relationship with clinical variables in patients with panic disorder (PD)." | 3.74 | Decreased GABA levels in anterior cingulate and basal ganglia in medicated subjects with panic disorder: a proton magnetic resonance spectroscopy (1H-MRS) study. ( Ham, BJ; Kim, DJ; Kim, JE; Kim, JH; Kim, N; Kim, SJ; Lee, JY; Lyoo, IK; Sung, Y; Yoon, SJ, 2007) |
| "There is preclinical evidence and indirect clinical evidence implicating gamma-aminobutyric acid (GABA) in the pathophysiology and treatment of human panic disorder." | 3.71 | Reductions in occipital cortex GABA levels in panic disorder detected with 1h-magnetic resonance spectroscopy. ( Almai, A; Behar, KL; Charney, DS; Goddard, AW; Krystal, JH; Mason, GF; Petroff, OA; Rothman, DL, 2001) |
| "Total occipital cortical GABA levels (GABA plus homocarnosine) were assessed in 14 unmedicated patients with panic disorder who did not have major depression and 14 retrospectively age- and sex-matched control subjects using spatially localized (1)H-magnetic resonance spectroscopy." | 3.71 | Reductions in occipital cortex GABA levels in panic disorder detected with 1h-magnetic resonance spectroscopy. ( Almai, A; Behar, KL; Charney, DS; Goddard, AW; Krystal, JH; Mason, GF; Petroff, OA; Rothman, DL, 2001) |
| "Patients with panic disorder had a 22% reduction in total occipital cortex GABA concentration (GABA plus homocarnosine) compared with controls." | 3.71 | Reductions in occipital cortex GABA levels in panic disorder detected with 1h-magnetic resonance spectroscopy. ( Almai, A; Behar, KL; Charney, DS; Goddard, AW; Krystal, JH; Mason, GF; Petroff, OA; Rothman, DL, 2001) |
| " We employed flumazenil radiolabeled with carbon 11, a radioligand that labels the benzodiazepine site on the GABA(A) receptor, and fully quantitative, high-sensitivity PET to test the hypothesis that central benzodiazepine site binding is decreased in medication-free patients with panic disorder." | 3.70 | Decreased brain GABA(A)-benzodiazepine receptor binding in panic disorder: preliminary results from a quantitative PET study. ( Bell, CJ; Cunningham, VJ; Jones, T; Liddle, PF; Malizia, AL; Nutt, DJ, 1998) |
| "These results must be considered preliminary but are congruous with previous clinical psychopharmacologic evidence of involvement of the benzodiazepine-GABA(A) receptor and demonstrate that decreased flumazenil binding at this site may underlie panic disorder." | 3.70 | Decreased brain GABA(A)-benzodiazepine receptor binding in panic disorder: preliminary results from a quantitative PET study. ( Bell, CJ; Cunningham, VJ; Jones, T; Liddle, PF; Malizia, AL; Nutt, DJ, 1998) |
| "Low levels of gamma-aminobutyric acid (GABA) in plasma have been associated with the presence of mood disorders in patients with major depressive disorder." | 3.69 | Plasma levels of gamma-aminobutyric acid and panic disorder. ( Davis, LL; Germine, M; Goddard, AW; Kramer, GL; Narayan, M; Petty, F; Woods, SW, 1996) |
| "Sodium valproate (VA) and clonazepam (CLZ) were combined in the treatment of 4 patients with panic disorders (PD) who were resistant to several antipanic drug treatments." | 3.68 | Sodium valproate and clonazepam for treatment-resistant panic disorder. ( Fontaine, R; Ontiveros, A, 1992) |
| " Benzodiazepines are fast and effective anxiolytic drugs; however, their long-term use is limited by the development of tolerance and withdrawal symptoms." | 2.74 | Translocator protein (18 kD) as target for anxiolytics without benzodiazepine-like side effects. ( Baghai, TC; Bertaina-Anglade, V; Chaperon, F; Eser, D; Floesser, A; Gentsch, C; Holsboer, F; Kalkman, HO; Kiese, B; Kucher, K; La Rochelle, CD; Landgraf, R; McAllister, KH; Nothdurfter, C; Rammes, G; Rupprecht, R; Schüle, C; Schumacher, M; Troxler, T; Tuerck, D; Uzunov, V, 2009) |
| "Gabapentin treatment appeared to be effective in blocking a lactate-induced panic response but did not alter the magnitude or time course of an abnormal brain lactate response to lactate infusion in all subjects." | 2.70 | Brain metabolic changes during lactate-induced panic: effects of gabapentin treatment. ( Dager, SR; Friedman, SD; Layton, ME, 2001) |
| "Pharmacologic treatments for panic disorder and social phobia have been available since the early 1960s." | 2.40 | Panic disorder and social phobia: current treatments and new strategies. ( Connor, KM; Davidson, JR; Sutherland, SM, 1998) |
| "Panic disorder is a severe anxiety disorder characterized by recurrent panic attacks that can be consistently provoked with intravenous (i." | 1.36 | Changes in central sodium and not osmolarity or lactate induce panic-like responses in a model of panic disorder. ( Dimicco, JA; Fitz, SD; Herman, JP; Johnson, PL; Molosh, AI; Shekhar, A, 2010) |
| "Panic disorder is associated with reductions in total occipital cortex GABA levels." | 1.31 | Reductions in occipital cortex GABA levels in panic disorder detected with 1h-magnetic resonance spectroscopy. ( Almai, A; Behar, KL; Charney, DS; Goddard, AW; Krystal, JH; Mason, GF; Petroff, OA; Rothman, DL, 2001) |
| " A significant improvement was found in the symptomatology of these patients, but relapses occurred when CLZ dosage was reduced." | 1.28 | Sodium valproate and clonazepam for treatment-resistant panic disorder. ( Fontaine, R; Ontiveros, A, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (28.57) | 18.2507 |
| 2000's | 15 (35.71) | 29.6817 |
| 2010's | 15 (35.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Waider, J | 1 |
| Popp, S | 1 |
| Lange, MD | 1 |
| Kern, R | 1 |
| Kolter, JF | 1 |
| Kobler, J | 1 |
| Donner, NC | 1 |
| Lowe, KR | 1 |
| Malzbender, JH | 1 |
| Brazell, CJ | 1 |
| Arnold, MR | 1 |
| Aboagye, B | 1 |
| Schmitt-Böhrer, A | 1 |
| Lowry, CA | 2 |
| Pape, HC | 1 |
| Lesch, KP | 1 |
| da Silva, JA | 1 |
| Almada, RC | 1 |
| de Figueiredo, RM | 1 |
| Coimbra, NC | 1 |
| Preuss, N | 1 |
| Salehi, B | 1 |
| van der Veen, JW | 2 |
| Shen, J | 2 |
| Drevets, WC | 2 |
| Hodgkinson, C | 1 |
| Goldman, D | 1 |
| Hasler, G | 2 |
| Shin, YW | 2 |
| Dzemidzic, M | 2 |
| Jo, HJ | 1 |
| Long, Z | 2 |
| Medlock, C | 2 |
| Dydak, U | 2 |
| Goddard, AW | 7 |
| Yamashita, PS | 1 |
| Spiacci, A | 1 |
| Hassel, JE | 1 |
| Zangrossi, H | 2 |
| Geraci, M | 1 |
| Pine, D | 1 |
| Davies, SJ | 1 |
| Esler, M | 1 |
| Nutt, DJ | 2 |
| Rupprecht, R | 1 |
| Rammes, G | 1 |
| Eser, D | 1 |
| Baghai, TC | 1 |
| Schüle, C | 1 |
| Nothdurfter, C | 1 |
| Troxler, T | 1 |
| Gentsch, C | 1 |
| Kalkman, HO | 1 |
| Chaperon, F | 1 |
| Uzunov, V | 1 |
| McAllister, KH | 1 |
| Bertaina-Anglade, V | 1 |
| La Rochelle, CD | 1 |
| Tuerck, D | 1 |
| Floesser, A | 1 |
| Kiese, B | 1 |
| Schumacher, M | 1 |
| Landgraf, R | 1 |
| Holsboer, F | 1 |
| Kucher, K | 1 |
| Casarotto, PC | 1 |
| de Bortoli, VC | 1 |
| Corrêa, FM | 1 |
| Resstel, LB | 1 |
| Molosh, AI | 1 |
| Johnson, PL | 4 |
| Fitz, SD | 4 |
| Dimicco, JA | 2 |
| Herman, JP | 1 |
| Shekhar, A | 6 |
| Kuehn, BM | 1 |
| Möhler, H | 1 |
| Nakazato, A | 1 |
| Chaki, S | 1 |
| Steckler, T | 2 |
| Schmidt, M | 1 |
| Stein, M | 1 |
| Lightfoot, JD | 1 |
| Hay, E | 1 |
| Engleman, EA | 1 |
| Svensson, KA | 1 |
| Schkeryantz, JM | 1 |
| Joos, AA | 1 |
| Zeeck, A | 1 |
| Pigott, TA | 1 |
| Bell, EC | 1 |
| Baker, GB | 1 |
| Poag, C | 1 |
| Bellavance, F | 1 |
| Khudabux, J | 1 |
| Le Mellédo, JM | 1 |
| Mason, GF | 3 |
| Rothman, DL | 3 |
| Behar, KL | 3 |
| Petroff, OA | 2 |
| Krystal, JH | 4 |
| Appel, M | 1 |
| Gueorguieva, R | 1 |
| Sajdyk, TJ | 1 |
| Keim, SR | 2 |
| Kelley, PE | 1 |
| Gehlert, DR | 1 |
| Brack, KE | 1 |
| Lovick, TA | 1 |
| Himmerich, H | 1 |
| Nickel, T | 1 |
| Dalal, MA | 1 |
| Müller, MB | 1 |
| Ham, BJ | 1 |
| Sung, Y | 1 |
| Kim, N | 1 |
| Kim, SJ | 1 |
| Kim, JE | 1 |
| Kim, DJ | 1 |
| Lee, JY | 1 |
| Kim, JH | 1 |
| Yoon, SJ | 1 |
| Lyoo, IK | 1 |
| Johnson, P | 1 |
| Lowry, C | 1 |
| Truitt, W | 1 |
| Johnson, MR | 1 |
| Lydiard, RB | 2 |
| Ballenger, JC | 1 |
| Rimón, R | 1 |
| Lepola, U | 1 |
| Jolkkonen, J | 1 |
| Halonen, T | 1 |
| Riekkinen, P | 1 |
| Narayan, M | 1 |
| Woods, SW | 1 |
| Germine, M | 1 |
| Kramer, GL | 2 |
| Davis, LL | 1 |
| Petty, F | 2 |
| Deutsch, DN | 1 |
| Charney, DS | 2 |
| Simon, JR | 1 |
| McBride, WJ | 1 |
| Heninger, GR | 1 |
| Pollack, MH | 2 |
| Matthews, J | 1 |
| Scott, EL | 1 |
| Malizia, AL | 1 |
| Cunningham, VJ | 1 |
| Bell, CJ | 1 |
| Liddle, PF | 1 |
| Jones, T | 1 |
| Akiyoshi, J | 1 |
| Pande, AC | 1 |
| Crockatt, J | 1 |
| Greiner, M | 1 |
| Chouinard, G | 1 |
| Taylor, CB | 1 |
| Dager, SR | 2 |
| Shiovitz, T | 1 |
| Almai, A | 1 |
| Tsuboi, K | 1 |
| Masuko, M | 1 |
| Layton, ME | 1 |
| Friedman, SD | 1 |
| Davidson, JR | 1 |
| Connor, KM | 1 |
| Sutherland, SM | 1 |
| Roy-Byrne, PP | 1 |
| Cowley, DS | 1 |
| Hommer, D | 1 |
| Greenblatt, DJ | 1 |
| Ontiveros, A | 1 |
| Fontaine, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Role of Orexin in Human Panic Disorder[NCT02593682] | Phase 4 | 3 participants (Actual) | Interventional | 2016-05-31 | Completed | ||
| Effect of Gabapentin on Postoperative Opioid Analgesic Use and Pain in Adolescents Undergoing Tonsillectomy[NCT05024825] | Phase 4 | 17 participants (Actual) | Interventional | 2017-08-04 | Terminated (stopped due to recruitment target not met.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 reviews available for gamma-aminobutyric acid and Panic Disorder
| Article | Year |
|---|---|
Anxiety--bridging the heart/mind divide.
Topics: Animals; Anxiety Disorders; Brain; Cardiovascular Diseases; gamma-Aminobutyric Acid; Heart; Humans; | 2010 |
The rise of a new GABA pharmacology.
Topics: Analgesics; Benzodiazepines; Diazepam Binding Inhibitor; GABA Agents; gamma-Aminobutyric Acid; Human | 2011 |
Pharmacologic treatment of panic disorder.
Topics: Antidepressive Agents, Tricyclic; Anxiety; Behavior Therapy; Benzodiazepines; gamma-Aminobutyric Aci | 2010 |
Anxiety disorders in women.
Topics: Agoraphobia; Anti-Anxiety Agents; Anxiety Disorders; Comorbidity; Female; gamma-Aminobutyric Acid; H | 2003 |
Panic disorder. Pathophysiology and drug treatment.
Topics: Benzodiazepines; Cholecystokinin; Cognitive Behavioral Therapy; Dopamine; gamma-Aminobutyric Acid; H | 1995 |
The biological basis of panic disorder.
Topics: Brain; Caffeine; Carbon Dioxide; gamma-Aminobutyric Acid; Humans; Lactates; Norepinephrine; Panic Di | 1996 |
[Neuropharmacological and genetic study of panic disorder].
Topics: Cholecystokinin; Corticotropin-Releasing Hormone; Diagnostic Imaging; gamma-Aminobutyric Acid; Human | 1999 |
[Panic disorder and antidepressants].
Topics: Antidepressive Agents, Tricyclic; gamma-Aminobutyric Acid; Humans; Norepinephrine; Panic Disorder; P | 2001 |
Panic disorder and social phobia: current treatments and new strategies.
Topics: Acetates; Amines; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Cost-Benefit Analysis; Cycl | 1998 |
6 trials available for gamma-aminobutyric acid and Panic Disorder
| Article | Year |
|---|---|
Translocator protein (18 kD) as target for anxiolytics without benzodiazepine-like side effects.
Topics: Adult; Alprazolam; Animals; Anti-Anxiety Agents; Benzodiazepines; Cell Line; Drug Tolerance; gamma-A | 2009 |
Response to flumazenil in the late luteal phase and follicular phase of the menstrual cycle in healthy control females.
Topics: Adult; Double-Blind Method; Female; Flumazenil; Follicular Phase; GABA Modulators; gamma-Aminobutyri | 2004 |
Cerebrospinal fluid gamma-aminobutyric acid in patients with panic disorder.
Topics: Adult; Alprazolam; Antidepressive Agents, Tricyclic; Female; GABA Modulators; gamma-Aminobutyric Aci | 1995 |
Placebo-controlled study of gabapentin treatment of panic disorder.
Topics: Acetates; Adolescent; Adult; Aged; Agoraphobia; Amines; Anti-Anxiety Agents; Cyclohexanecarboxylic A | 2000 |
Brain metabolic changes during lactate-induced panic: effects of gabapentin treatment.
Topics: Acetates; Adult; Amines; Arousal; Aspartic Acid; Brain; Cyclohexanecarboxylic Acids; Double-Blind Me | 2001 |
Effect of acute and chronic benzodiazepines on plasma GABA in anxious patients and controls.
Topics: Adult; Alprazolam; Anti-Anxiety Agents; Anxiety Disorders; Diazepam; gamma-Aminobutyric Acid; Humans | 1992 |
27 other studies available for gamma-aminobutyric acid and Panic Disorder
| Article | Year |
|---|---|
Genetically driven brain serotonin deficiency facilitates panic-like escape behavior in mice.
Topics: Agoraphobia; Amygdala; Animals; Anxiety; Electroshock; Escape Reaction; Fear; gamma-Aminobutyric Aci | 2017 |
Blockade of synaptic activity in the neostriatum and activation of striatal efferent pathways produce opposite effects on panic attack-like defensive behaviours evoked by GABAergic disinhibition in the deep layers of the superior colliculus.
Topics: Animals; Behavior, Animal; Cobalt; Corpus Striatum; Efferent Pathways; gamma-Aminobutyric Acid; Male | 2018 |
Associations between prefrontal γ-aminobutyric acid concentration and the tryptophan hydroxylase isoform 2 gene, a panic disorder risk allele in women.
Topics: Adult; Alleles; Depressive Disorder, Major; Female; gamma-Aminobutyric Acid; Genetic Association Stu | 2013 |
Increased resting-state functional connectivity between the anterior cingulate cortex and the precuneus in panic disorder: resting-state connectivity in panic disorder.
Topics: Adult; Female; gamma-Aminobutyric Acid; Gyrus Cinguli; Humans; Magnetic Resonance Imaging; Magnetic | 2013 |
Disinhibition of the rat prelimbic cortex promotes serotonergic activation of the dorsal raphe nucleus and panicolytic-like behavioral effects.
Topics: Animals; Anxiety; Anxiety Disorders; Behavior, Animal; Dorsal Raphe Nucleus; Escape Reaction; gamma- | 2017 |
Prefrontal cortical gamma-aminobutyric Acid levels in panic disorder determined by proton magnetic resonance spectroscopy.
Topics: Adolescent; Adult; Aspartic Acid; Brain Chemistry; Choline; Female; gamma-Aminobutyric Acid; Humans; | 2009 |
Panicolytic-like effect of BDNF in the rat dorsal periaqueductal grey matter: the role of 5-HT and GABA.
Topics: Animals; Brain-Derived Neurotrophic Factor; gamma-Aminobutyric Acid; Humans; Injections, Intraventri | 2010 |
Changes in central sodium and not osmolarity or lactate induce panic-like responses in a model of panic disorder.
Topics: Action Potentials; Animals; Cardiovascular Physiological Phenomena; Disease Models, Animal; Dorsomed | 2010 |
Hormone may play role in triggering panic attacks.
Topics: Animals; gamma-Aminobutyric Acid; Humans; Intracellular Signaling Peptides and Proteins; Neuropeptid | 2010 |
A selective, non-peptide CRF receptor 1 antagonist prevents sodium lactate-induced acute panic-like responses.
Topics: Animals; Anxiety; Behavior, Animal; Cardiovascular Physiological Phenomena; Dorsomedial Hypothalamic | 2011 |
Group II metabotropic glutamate receptor type 2 allosteric potentiators prevent sodium lactate-induced panic-like response in panic-vulnerable rats.
Topics: Alprazolam; Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Cardiovascular System; gamma-Am | 2013 |
Gabapentin in somatoform and panic disorder.
Topics: Amines; Anti-Anxiety Agents; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Human | 2013 |
Decreased GABA levels in anterior cingulate cortex/medial prefrontal cortex in panic disorder.
Topics: Adult; Aged; Analysis of Variance; Case-Control Studies; Female; gamma-Aminobutyric Acid; Gyrus Cing | 2013 |
Family psychopathology and magnitude of reductions in occipital cortex GABA levels in panic disorder.
Topics: gamma-Aminobutyric Acid; Humans; Occipital Lobe; Panic Disorder | 2004 |
Impaired GABA neuronal response to acute benzodiazepine administration in panic disorder.
Topics: Adult; Benzodiazepines; Brain; Clonazepam; Female; GABA Modulators; gamma-Aminobutyric Acid; Glutama | 2004 |
Angiotensin-II is a putative neurotransmitter in lactate-induced panic-like responses in rats with disruption of GABAergic inhibition in the dorsomedial hypothalamus.
Topics: Angiotensin II; Animals; Behavior, Animal; gamma-Aminobutyric Acid; Hypothalamus; Lactic Acid; Male; | 2006 |
Neuronal excitability in the periaqueductal grey matter during the estrous cycle in female Wistar rats.
Topics: Anesthesia; Animals; Bicuculline; Biotin; Blood Pressure; Electrophysiology; Estrous Cycle; Female; | 2007 |
[Gabapentin treatment in a female patient with panic disorder and adverse effects under carbamazepine during benzodiazepine withdrawal].
Topics: Aged; Alprazolam; Amines; Antimanic Agents; Benzodiazepines; Carbamazepine; Chemical and Drug Induce | 2007 |
Decreased GABA levels in anterior cingulate and basal ganglia in medicated subjects with panic disorder: a proton magnetic resonance spectroscopy (1H-MRS) study.
Topics: Adult; Basal Ganglia; Case-Control Studies; Choline; Female; gamma-Aminobutyric Acid; Gyrus Cinguli; | 2007 |
Disruption of GABAergic tone in the dorsomedial hypothalamus attenuates responses in a subset of serotonergic neurons in the dorsal raphe nucleus following lactate-induced panic.
Topics: Allylglycine; Animals; Anxiety Disorders; gamma-Aminobutyric Acid; Male; Neurons; Panic Disorder; Pr | 2008 |
Plasma levels of gamma-aminobutyric acid and panic disorder.
Topics: Adult; Agoraphobia; Anxiety Disorders; Female; gamma-Aminobutyric Acid; Humans; Male; Middle Aged; M | 1996 |
Dorsomedial hypothalamic GABA dysfunction produces physiological arousal following sodium lactate infusions.
Topics: Allylglycine; Animals; Arousal; Blood Pressure; Dorsomedial Hypothalamic Nucleus; GABA Antagonists; | 1996 |
Catecholamines and pathogenesis in panic disorder.
Topics: Catecholamines; Epinephrine; gamma-Aminobutyric Acid; Humans; Norepinephrine; Panic Disorder; Recept | 1998 |
Gabapentin as a potential treatment for anxiety disorders.
Topics: Acetates; Adult; Alprazolam; Amines; Anticonvulsants; Anxiety Disorders; Cyclohexanecarboxylic Acids | 1998 |
Decreased brain GABA(A)-benzodiazepine receptor binding in panic disorder: preliminary results from a quantitative PET study.
Topics: Adult; Aged; Brain; Carbon Radioisotopes; Cerebral Cortex; Female; Flumazenil; Functional Laterality | 1998 |
Reductions in occipital cortex GABA levels in panic disorder detected with 1h-magnetic resonance spectroscopy.
Topics: Adult; Agoraphobia; Ambulatory Care; Carnosine; Female; gamma-Aminobutyric Acid; Humans; Magnetic Re | 2001 |
Sodium valproate and clonazepam for treatment-resistant panic disorder.
Topics: Adult; Agoraphobia; Clonazepam; Drug Synergism; Drug Therapy, Combination; Female; gamma-Aminobutyri | 1992 |